Yescarta denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for yescarta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Yescarta: Duplicate Therapy

Yescarta (axicabtagene ciloleucel) is a CAR-T cell therapy approved for certain relapsed or refractory large B-cell lymphomas and follicular lymphoma. A "duplicate therapy" denial typically arises when UHC's system identifies that another oncologic agent — often another CAR-T product or a recently administered therapy — appears to overlap with Yescarta in purpose or timing. This can also trigger if a prior authorization for a different lymphoma therapy is active simultaneously.

## Why This Is Appealable

CAR-T therapies are highly individualized and mechanism-specific. No two CAR-T products are clinically interchangeable, and Yescarta's approval is for specific indications that may not be covered by another product. If the "duplicate" identified by UHC is a different agent altogether, your oncologist can document the clinical distinction and the necessity of Yescarta specifically. Duplicate-therapy denials in oncology are frequently resolved at the internal appeal stage with clear prescriber documentation.

## Federal Appeal Framework

• Internal appeal: File under ACA §2719 / ERISA §503 within the timeframe on your denial notice. For urgent oncology cases, request expedited review — UHC must respond within 72 hours.
• External review: If internal appeal is denied, an Independent Review Organization can review the decision. The standard external review window is up to four months from the final internal denial. Expedited external review is available given the serious nature of the underlying condition.

## Documentation to Collect

1. Diagnosis and staging records — pathology reports, PET/CT imaging reports, and bone marrow biopsy results confirming the current diagnosis and disease status. 2. Treatment history — a complete list of prior lines of therapy with dates, regimens, and response assessments (complete remission, partial response, progression, or relapse dates). 3. Identification of the alleged duplicate — obtain from UHC exactly which therapy they consider duplicative and why. This is critical to crafting a targeted rebuttal. 4. Clinical distinction letter — your oncologist should explain specifically why Yescarta is not duplicative of the identified therapy, addressing mechanism, indication, and clinical necessity. 5. Applicable guideline reference — your oncologist should note that the relevant oncology guideline organization (e.g., NCCN) supports Yescarta in your clinical context, without citing specific version numbers or statistics.

## Criteria-Mapping Structure

Address the duplicate-therapy claim directly: identify what UHC flagged, explain the clinical difference, and map Yescarta's FDA-approved indication to your confirmed diagnosis and treatment history. This rebuttal structure is more effective than a general medical necessity argument.